Arcturus Therapeutics (ARCT) vs C4 Therapeutics (CCCC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
C4 Therapeutics (CCCC) has outperformed Arcturus Therapeutics (ARCT) over the past year, gaining 24.8% versus a loss of 37.6%. Over five years, ARCT leads with a -72.0% price change compared with -93.6% for CCCC. Arcturus Therapeutics is the larger company by market cap ($362.8 million vs $346.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARCT | CCCC |
|---|---|---|
| Share price | $12.77 | $2.82 |
| Market cap | $362.82M | $346.93M |
| 1-day change | -1.81% | -2.08% |
| YTD return | +108.24% | +47.64% |
| 1-year return | -37.64% | +24.78% |
| 5-year return | -71.98% | -93.57% |
| EPS (TTM) | $-3.33 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.17 | $5.17 |
| 52-week low | $5.50 | $1.69 |
| Distance from 52-week high | -47.19% | -45.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +81.75% | +372.70% |
| Average volume | 938.55K | 2.38M |
| Shares outstanding | 28.42M | 123.03M |
| Employees | 106 | 104 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CCCC has outperformed ARCT by 62.4 percentage points over the past year.
About Arcturus Therapeutics
ARCT stock →Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees
ARCT vs CCCC FAQ
Which is bigger, Arcturus Therapeutics or C4 Therapeutics?
Arcturus Therapeutics (ARCT) is larger, with a market capitalization of $362.82M compared with $346.93M for C4 Therapeutics (CCCC).
Which stock has performed better over the past year, ARCT or CCCC?
CCCC returned +24.78% over the past 12 months, compared with -37.64% for ARCT (price return, excluding dividends). Past performance does not predict future results.
Are Arcturus Therapeutics and C4 Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Arcturus Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for C4 Therapeutics.